{
  "meta": {
    "title": "Rh_Negative_Pregnancy",
    "url": "https://brainandscalpel.vercel.app/rh-negative-pregnancy-b8b03bbc.html",
    "scrapedAt": "2025-11-29T18:26:44.967Z"
  },
  "questions": [
    {
      "id": 18818,
      "choices": [
        {
          "id": 75232,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Give another dose of Anti-D 72 h postpartum if the baby&rsquo;s blood group is Rh positive</span></span></span></span></p>"
        },
        {
          "id": 75233,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Give another dose of Anti-D 72 h postpartum irrespective of baby blood group.&nbsp;</span></span></span></span></p>"
        },
        {
          "id": 75234,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">No need of additional dose since she is ICT negative&nbsp;</span></span></span></span></p>"
        },
        {
          "id": 75235,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Given another dose of Anti-D 72 hours postpartum only if ICT is positive</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A Rh-negative mother, who has Indirect Coombs (ICT), negative was given Anti-D at 28 weeks pregnancy. Which of the following is the correct option regarding Anti-D prophylaxis?</span></span></p>",
      "unique_key": "Q4676755",
      "question_audio": null,
      "question_video": null,
      "map_id": 18655,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. A. Give another dose of Anti-D 72 h postpartum if the baby&rsquo;s blood group is Rh positive</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Prophylaxis: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Anti D (300 mcg IM) given at 28 weeks (If ICT is negative)</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Repeated within 72 h after delivery if baby is Rh positive</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">300 mcg neutralizes 30 ml of fetal blood (15 ml of fetal red cells)</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Avoid past dates; Avoid methylergometrine</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Delivery is the cause of 90% of feto maternal haemorrhage</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Also given after inciting events (When feto maternal haemorrhage can happen)</span></span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Spontaneous/ induced abortion/ MTP/ fetal demise at any gestation</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ectopic pregnancy, Molar pregnancy</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Selective fetal reduction/ Amniocentesis/ Chorionic villous sampling</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">External cephalic version</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Manual removal of placenta</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Abruptio Placentae/ Abdominal trauma</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Let us look at each option:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Give another dose of Anti-D 72 h postpartum if the baby&rsquo;s blood group is Rh positive (Correct Answer):</span></strong><span style=\"font-size:12.0pt\"> If an Rh-negative mother delivers an Rh-positive baby, she is at risk of being sensitized to Rh-positive blood. Administering Anti-D within 72 hours postpartum can prevent Rh immunization in future pregnancies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Give another dose of Anti-D 72 h postpartum irrespective of baby blood group:</span></strong><span style=\"font-size:12.0pt\"> incorrect. The need for a postpartum dose of Anti-D depends on the baby&#39;s Rh status. If the baby is Rh-negative, the mother&#39;s body will not be exposed to Rh-positive antigens, and thus she would not require another dose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. No need for an additional dose since she is ICT negative:</span></strong><span style=\"font-size:12.0pt\"> incorrect. Being ICT &nbsp;negative before delivery means the mother has not yet formed antibodies against Rh-positive blood. However, this does not preclude the need for postpartum prophylaxis if the baby is Rh-positive.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Given another dose of Anti-D 72 hours postpartum only if ICT is positive:</span></strong><span style=\"font-size:12.0pt\"> This statement is incorrect. Anti-D is given postpartum to prevent the mother from developing antibodies, not because she has already developed them. An ICT positive result would indicate that the mother has already been sensitized, which is what the prophylaxis aims to prevent.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong><span style=\"font-size:12.0pt\"> The administration of Anti-D prophylaxis to an Rh-negative mother is critical for preventing Rh immunization. If the newborn is Rh-positive, the mother should receive another dose of Anti-D within 72 hours postpartum, irrespective of her ICT status at the time of delivery. This strategy is essential for safeguarding maternal health in subsequent pregnancies.</span></span></span></p>\r\n\r\n<p style=\"margin-left:96px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ref: Page no 305, Williams Obstetrics 25<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 75232,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18821,
      "choices": [
        {
          "id": 75244,
          "text": "<p><span style=\"color:black;font-size:12.0pt;\">Repeat ICT after 2 weeks</span></p>"
        },
        {
          "id": 75245,
          "text": "<p><span style=\"color:black;font-size:12.0pt;\">Give steroid cover and deliver</span></p>"
        },
        {
          "id": 75246,
          "text": "<p><span style=\"color:black;font-size:12.0pt;\">Perform ultrasound assessment including MCA-PSV</span></p>"
        },
        {
          "id": 75247,
          "text": "<p><span style=\"color:black;font-size:12.0pt;\">Perform intrauterine transfusion</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 25-year G2A1 at 28 weeks with blood group B negative gets an ICT done. The report is 1:32. What is the next best step?</span></p>",
      "unique_key": "Q2409324",
      "question_audio": null,
      "question_video": null,
      "map_id": 18656,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C. Perform ultrasound assessment including MCA-PSV</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Management of an already sensitized pregnancy (i.e., ICT positive)</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Check ICT monthly till 24 weeks and weekly thereafter till critical titers are reached</span></li><li><span style=\"background-color:transparent;font-size:12pt;\">In ICT, higher titres indicate greater antibody concentration.</span></li><li><span style=\"font-size:12.0pt;\">Critical titre 1:32 &gt; 1:16</span></li><li><span style=\"font-size:12.0pt;\">Once critical titre is reached - Check Peak systolic velocity of Middle cerebral artery (PSV of MCA)</span></li><li><span style=\"font-size:12.0pt;\">If PSV of MCA &gt; 1.5 MoM – Cordocentesis and check fetal Hematocrit (Hct)</span></li><li><span style=\"font-size:12.0pt;\">If Hct of fetal blood is &lt; 30% - Intra uterine transfusion with O negative blood is transfused</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Let us look at each option:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Repeat ICT after 2 weeks:&nbsp;</strong>While repeating the ICT could provide additional information on whether the antibody levels are increasing, it would not give immediate insight into the fetal condition at the time.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Give steroid cover and deliver:&nbsp;</strong>Administering steroids and delivering the baby is a course of action for cases where there's evidence of fetal distress or significant maturity, and the pregnancy is at a viable stage. At 28 weeks, unless there's urgent evidence of fetal compromise, immediate delivery is not typically the first step.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Perform ultrasound assessment including MCA-PSV (Correct Answer):&nbsp;</strong>Performing an ultrasound to assess the fetus, including the Middle Cerebral Artery Peak Systolic Velocity (MCA-PSV), helps determine if the fetus is anemic. An elevated MCA-PSV is indicative of fetal anemia and may necessitate further interventions. This is a non-invasive way to monitor the fetus and is the next best step in this case.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Perform intrauterine transfusion:&nbsp;</strong>This is a treatment for fetal anemia, not a diagnostic step. It would be considered if there's evidence of significant fetal anemia and distress, typically indicated by an abnormal MCA-PSV and other ultrasound findings.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In a pregnant Rh-negative woman with a positive ICT, the next best step is to perform an ultrasound assessment including MCA-PSV to check for fetal anemia. This approach allows for timely and non-invasive monitoring of the fetus, which is crucial for deciding on further management to prevent fetal morbidity and mortality.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Page no 303, Williams Obstetrics 25<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 75246,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18822,
      "choices": [
        {
          "id": 75248,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Cordocentesis &amp; Intrauterine transfusion (if necessary)</span></span></span></span></p>"
        },
        {
          "id": 75249,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Repeat ICT after 2 weeks.</span></span></span></span></p>"
        },
        {
          "id": 75250,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Give maternal steroid and deliver.</span></span></span></span></p>"
        },
        {
          "id": 75251,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Repeat MCA-PSV after 2 weeks.</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 32-year-old G3A2, Rh Negative, pregnant lady presents at 31 weeks pregnancy with an Indirect Coomb&rsquo;s Test (ICT) titer of 1:64. Ultrasound assessment shows MCA PSV more than 1.5 MOM. What is the next step in management?</span></span></span></p>",
      "unique_key": "Q6729305",
      "question_audio": null,
      "question_video": null,
      "map_id": 18657,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. A. Cordocentesis &amp; Intrauterine transfusion (if necessary)</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Management of an already sensitized pregnancy (i.e., ICT positive)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Check ICT monthly till 24 weeks and weekly thereafter till critical titers are reached.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Critical titer is &gt; 1: 16</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">Once critical titer is reached - Check Peak systolic velocity of Middle cerebral artery (PSV of MCA) </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">If PSV of MCA &gt; 1.5 MoM &ndash; Cordocentesis and check fetal Hematocrit (Hct)</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\">If Hct of fetal blood is &lt; 30% - Intra uterine transfusion with O negative blood is transfused</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:#374151\">Let us look at each option:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option <span style=\"color:#374151\">A. Cordocentesis &amp; Intrauterine transfusion (if necessary) (Correct Answer):&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:#374151\">Given the high ICT titer and the ultrasound showing an MCA PSV (Middle Cerebral Artery Peak Systolic Velocity) of more than 1.5 MOM (multiples of the median), there&#39;s a high risk of fetal anemia. Cordocentesis (fetal blood sampling) is done to confirm anemia and intrauterine transfusion is performed if necessary. This is the most direct approach to treat potential fetal anemia.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option <span style=\"color:#374151\">B. Repeat ICT after 2 weeks:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:#374151\">While repeating the ICT might provide information about the progression of the mother&#39;s antibody levels, it doesn&#39;t address the immediate concern of fetal well-being. Given the current findings, waiting two weeks could result in a delay in essential treatment.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option <span style=\"color:#374151\">C. Give maternal steroid and deliver:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:#374151\">Administering steroids and delivering the baby is generally considered in cases of fetal distress or when nearing term. At 31 weeks, unless there&#39;s urgent evidence of severe fetal compromise, immediate delivery is not typically the first choice.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option <span style=\"color:#374151\">D. Repeat MCA-PSV after 2 weeks:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:#374151\">Waiting two weeks to repeat the MCA-PSV could delay necessary intervention. The current MCA PSV already indicates a high risk of fetal anemia, necessitating more immediate action.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"color:#374151\">Educational Objective:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"color:#374151\">In cases of suspected fetal anemia due to Rh incompatibility, as indicated by high maternal ICT titers and abnormal MCA PSV, cordocentesis and potential intrauterine transfusion are vital for direct assessment and management of fetal anemia. This approach is crucial in preventing fetal morbidity and mortality associated with severe anemia</span></span><span style=\"font-size:12.0pt\"><span style=\"color:#374151\">.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ref: Page no 303, Williams Obstetrics 25<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 75248,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18827,
      "choices": [
        {
          "id": 75268,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">MTP at 63 days</span></span></span></span></p>"
        },
        {
          "id": 75269,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Manual removal of placenta</span></span></span></span></p>"
        },
        {
          "id": 75270,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Amniocentesis at 16 weeks</span></span></span></span></p>"
        },
        {
          "id": 75271,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Intrauterine transfusion at 28 weeks</span></span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-D prophylaxis is required in all the cases except: </span></span></p>",
      "unique_key": "Q5577397",
      "question_audio": null,
      "question_video": null,
      "map_id": 18658,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. D. Intrauterine transfusion at 28 weeks</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Anti D (300 mcg IM) given at 28 weeks (If ICT is negative)</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Repeated within 72 h after delivery if baby is Rh positive</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">300 mcg neutralizes 30 ml of fetal blood (15 ml of fetal red cells)</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Avoid past dates; Avoid methyl-ergometrine</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Delivery is the cause of 90% of feto maternal haemorrhage</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Also given after inciting events (When feto maternal haemorrhage can happen)</span></span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Spontaneous/ induced abortion/ MTP/ fetal demise at any gestation</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ectopic pregnancy, Molar pregnancy</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Selective fetal reduction/ Amniocentesis/ Chorionic villous sampling</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">External cephalic version</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Manual removal of placenta</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Abruptio Placentae/ Abdominal trauma</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Let us look at each option :</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option <span style=\"color:#374151\">A. MTP at 63 days</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">, <strong>B. Manual removal of placenta and C. Amniocentesis at 16 weeks</strong> can all lead to mixing of fetal and maternal blood. Therefore, Anti-D prophylaxis is recommended for Rh-negative women undergoing these &nbsp;procedure.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option <span style=\"color:#374151\">D. Intrauterine transfusion at 28 weeks</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">: Intrauterine transfusion is performed for the treatment of fetal conditions, often involving direct fetal blood transfusion. It does not typically involve a risk of fetal-maternal blood mixing to the extent that would require Anti-D prophylaxis for the mother. Therefore, Anti-D prophylaxis is generally not required in this scenario.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Educational Objective:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Anti-D immunoglobulin is vital for preventing Rh sensitization in Rh-negative women in situations where there&#39;s a risk of fetal-maternal blood mixing, such as MTP, manual removal of the placenta, and amniocentesis. It is generally not required during intrauterine transfusion as this procedure does not typically involve significant fetal-maternal blood mixing</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 305, Williams Obstetrics 25<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 75271,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18830,
      "choices": [
        {
          "id": 75280,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Immediate delivery&nbsp;</span></span></span></span></p>"
        },
        {
          "id": 75281,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Intrauterine transfusion&nbsp;</span></span></span></span></p>"
        },
        {
          "id": 75282,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Repeat amniocentesis after 1 week&nbsp;</span></span></span></span></p>"
        },
        {
          "id": 75283,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Plasmapheresis</span></span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">At 28 weeks gestation amniocentesis reveals&nbsp;</span></span></span>∆ <span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">OD 450 in Liley&#39;s zone 3. Which of the following is the best line of management? </span></span></span></p>",
      "unique_key": "Q3821357",
      "question_audio": null,
      "question_video": null,
      "map_id": 18659,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. B. Intrauterine transfusion</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Management of an already sensitized pregnancy (i.e., ICT positive)</span></span></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Check ICT monthly till 24 weeks and weekly thereafter till critical titers are reached.</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Critical titer is &gt; 1: 16</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Once critical titer is reached - Check Peak systolic velocity of Middle cerebral artery (PSV of MCA) </span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">If PSV of MCA &gt; 1.5 MoM &ndash; Cordocentesis and check fetal Hematocrit (Hct)</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">If Hct of fetal blood is &lt; 30% - Intra uterine transfusion with O negative blood is transfused</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Earlier, amniotic fluid spectrophotometry was done to determine the level of bilirubin in the amniotic fluid (indirectly assessing anemia) by spectrophotometry (bilirubin peaks at a wavelength of 450 nm). This value is then plotted on Liley&rsquo;s graph. (&gt; 27 weeks) or Queenans graph (&lt; 27 weeks)</span></span></span></span>\r\n\t\t<ul>\r\n\t\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Zone 1 &amp; lower level of zone 2: Repeat Amniocentesis after 2 weeks</span></span></span></span></li>\r\n\t\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Upper zone 2: Cordocentesis and Intra-uterine transfusion if Hct &lt; 30%</span></span></span></span></li>\r\n\t\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Zone 3: cordocentesis and Intra-uterine transfusion</span></span></span></span></li>\r\n\t\t</ul>\r\n\t\t</li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Let us look at each option:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option <span style=\"color:#374151\">A. Immediate delivery:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Delivering the baby at 28 weeks poses significant risks due to prematurity. Immediate delivery is typically considered when the fetus is at a viable gestational age and if intrauterine interventions are not possible or have failed.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option <span style=\"color:#374151\">B. Intrauterine transfusion (Correct Answer):&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">A &Delta; OD 450 in Liley&#39;s zone 3 indicates severe fetal anemia. Intrauterine transfusion is the preferred treatment for severe fetal anemia, especially at a gestational age where the fetus is not yet viable for delivery. This procedure involves transfusing blood directly to the fetus and can significantly improve fetal condition.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option <span style=\"color:#374151\">C. Repeat amniocentesis after 1 week:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Given that Liley&#39;s zone 3 represents severe fetal anemia, waiting another week without intervention could lead to worsening of the fetal condition. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option <span style=\"color:#374151\">D. Plasmapheresis</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">: Plasmapheresis is a procedure used to remove antibodies from the mother&#39;s blood. While it can be used in cases of immune-mediated diseases, it is not the first-line treatment for fetal anemia indicated by Liley&#39;s zone 3 findings. The efficacy of plasmapheresis in changing pregnancy outcomes in Rh isoimmunization is not conclusively established. Its use is limited to certain cases where the potential benefits outweigh the risks and complexities of the procedure</span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Educational Objective:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">In cases where amniocentesis reveals &Delta; OD 450 in Liley&#39;s zone 3, indicating severe fetal anemia, the best line of management is intrauterine transfusion. This intervention directly addresses the fetal anemia, providing immediate treatment to improve fetal health and outcome.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 303, Williams Obstetrics 25<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 75281,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18835,
      "choices": [
        {
          "id": 75300,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Anti &ndash; D prophylaxis should be given following delivery. </span></span></span></span></p>"
        },
        {
          "id": 75301,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Anti -D prophylaxis should be given as soon as possible only if she has not received Anti-D prophylaxis at 28 weeks. </span></span></span></span></p>"
        },
        {
          "id": 75302,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Anti-D prophylaxis should be given as soon as possible even if she has received Anti-D prophylaxis at 28 weeks. </span></span></span></span></p>"
        },
        {
          "id": 75303,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Anti-D prophylaxis is not required. </span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">A 34-year primigravida presents at 34 weeks with mild spotting. She is not in labor and the ultrasound shows the placenta in the upper segment. On evaluation, her blood group is B -negative and her husband is Rh positive. What is true regarding Anti &ndash; D prophylaxis?</span></span></span></span></p>",
      "unique_key": "Q1448192",
      "question_audio": null,
      "question_video": null,
      "map_id": 18660,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. C. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Anti-D prophylaxis should be given as soon as possible even if she has received Anti-D prophylaxis at 28 weeks. </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">(Ref: Page no 305, Williams Obstetrics 25<sup>th</sup> edition)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Prophylaxis: </span></span></strong></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Anti D (300 mcg IM) given at 28 weeks (If ICT is negative)</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Repeated within 72 h after delivery if baby is Rh positive</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">300 mcg neutralizes 30 ml of fetal blood (15 ml of fetal red cells)</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Avoid past dates; Avoid methylergometrine</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Delivery is the cause of 90% of feto maternal haemorrhage</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Also given after inciting events (When feto maternal haemorrhage can happen)</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Dose: 50 mcg &lt; 12 weeks and 300 mcg if &gt; 12 weeks</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Inciting events:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/23/screenshot-2024-04-23-183301.JPG\" style=\"height:299px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Let us look at each option:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option <span style=\"color:#374151\">A. Anti-D prophylaxis should be given following delivery</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">: While it&#39;s true that Anti-D is routinely given postpartum, this option overlooks the immediate need due to the current bleeding episode. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option <span style=\"color:#374151\">B. Anti-D prophylaxis should be given as soon as possible only if she has not received Anti-D prophylaxis at 28 weeks:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">This option is not accurate because the need for Anti-D prophylaxis in the event of antepartum bleeding is independent of whether she received prophylaxis at 28 weeks. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option <span style=\"color:#374151\">C. Anti-D prophylaxis should be given as soon as possible even if she has received Anti-D prophylaxis at 28 weeks (Correct Answer):&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">This is the correct approach. The woman should receive Anti-D prophylaxis as soon as possible following the bleeding episode, regardless of her having received a routine dose at 28 weeks. Each episode of potential fetal-maternal hemorrhage, such as bleeding in pregnancy, warrants a dose of Anti-D.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option <span style=\"color:#374151\">D. Anti-D prophylaxis is not required</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">: This is incorrect. Given the woman&rsquo;s Rh-negative status and the occurrence of antepartum bleeding, Anti-D prophylaxis is necessary.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Educational Objective:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Rh-negative pregnant women should receive Anti-D prophylaxis following any antepartum bleeding event to prevent Rh sensitization, regardless of prior prophylaxis at 28 weeks. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 305, Williams Obstetrics 25<sup>th</sup> edition)</span></span></strong></p>",
      "correct_choice_id": 75302,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18836,
      "choices": [
        {
          "id": 75304,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Kleihauer Betke test</span></span></span></span></p>"
        },
        {
          "id": 75305,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Rosette test</span></span></span></span></p>"
        },
        {
          "id": 75306,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Peripheral smear</span></span></span></span></p>"
        },
        {
          "id": 75307,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Flow cytometry</span></span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 32<span style=\"color:black\">-year</span> Rh negative woman had a normal delivery following which the following test was done. What is this test?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/06/13/2_fjIZJTk.jpg\" style=\"height:239px; width:300px\" /></span></span></p>",
      "unique_key": "Q3723190",
      "question_audio": null,
      "question_video": null,
      "map_id": 18661,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. A. Kleihauer Betke test</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Tests for feto-maternal haemorrhage are:</span></span></span></span>\r\n\r\n\t<ol>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Rosette test (Qualitative estimation)</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Kleihauer Betke test (acid elution test)</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Flow cytometry</span></span></span></span></li>\r\n\t</ol>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Let us look at each option : </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A. </span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Kleihauer-Betke</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Test</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: This test is performed to detect feto-maternal haemorrhage .On a microscope slide maternal blood is smeared and treated with an acid solution. The acid elutes (washes out) the adult hemoglobin, leaving only the fetal red blood cells which contain fetal hemoglobin intact. These fetal cells appear as bright pink or red against a pale background. The contrast makes them easy to identify and count under a microscope.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B.</span></strong> <strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Rosette Test:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> The Rosette test is a rapid, qualitative assay for feto-maternal haemorrhage. It involves mixing the mother&#39;s blood with anti-D (Rh) antibodies. If fetal Rh-positive cells are present in an Rh-negative mother&#39;s blood, they form rosettes around the anti-D coated red blood cells. These rosettes can be observed microscopically as clusters of cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Peripheral Smear</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: A drop of blood is spread thinly on a slide and typically stained with Wright&rsquo;s or Giemsa stain. Under the microscope, red blood cells appear as round, flat discs, white blood cells have varying shapes with distinct nuclei, and platelets look like small dots. </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">It is used to diagnose a range of blood disorders. However, it is not specifically used for detecting fetal-maternal hemorrhage .</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D.&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Flow Cytometry</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Flow cytometry doesn&#39;t produce a traditional image but rather generates a flow cytometric plot or graph. Cells or particles are tagged with fluorescent markers and passed through a laser beam, they scatter light and emit fluorescence. The resulting data are plotted on graphs, with each dot representing a cell or particle.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Educational Objective:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">The Kleihauer-Betke test is essential for detecting fetal red blood cells in the maternal circulation, especially in Rh-negative women post-delivery, to assess the need for appropriate Anti-D prophylaxis. This test helps in quantifying fetal-maternal hemorrhage and guides the management of Rh incompatibility</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 307, Williams Obstetrics 25<sup>th</sup> edition</span></span></strong></p>",
      "correct_choice_id": 75304,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18837,
      "choices": [
        {
          "id": 75308,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Anterior cerebral artery</span></span></span></span></p>"
        },
        {
          "id": 75309,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Middle cerebral artery</span></span></span></span></p>"
        },
        {
          "id": 75310,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Posterior cerebral artery</span></span></span></span></p>"
        },
        {
          "id": 75311,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Umbilical artery</span></span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Doppler of this fetal artery is useful in diagnosing fetal anemia</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/23/screenshot-2024-04-23-174558.JPG\" style=\"height:174px; width:300px\" /></span></span></p>",
      "unique_key": "Q9675560",
      "question_audio": null,
      "question_video": null,
      "map_id": 18662,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B. <span style=\"color:black\">Middle cerebral artery</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Doppler of the Middle cerebral artery is used for diagnosing anemia in Rh iso-immunized pregnancies.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Let us look at each option:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option A. Anterior cerebral artery:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Doppler studies of the anterior cerebral artery are generally used to assess cerebral perfusion and can indicate changes in brain blood flow</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option B. Middle cerebral artery (Correct Answer):&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Doppler ultrasound of the middle cerebral artery (MCA) is a key tool in diagnosing fetal anemia. The peak systolic velocity (PSV) in the MCA increases in anemic fetuses due to reduced blood viscosity and compensatory mechanisms to increase oxygen delivery to the brain.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option C. Posterior cerebral artery:</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">&nbsp; Its Doppler study is more relevant to cerebral vascular physiology and pathology but not specifically for anemia.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option D. Umbilical artery:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Doppler studies of the umbilical artery are crucial for assessing placental and fetal blood flow, particularly in cases of suspected placental insufficiency. While important for <strong>fetal well-being,</strong> it is not the primary tool for diagnosing fetal anemia.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Educational Objective:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Doppler ultrasound of the middle cerebral artery is a valuable non-invasive tool for diagnosing fetal anemia. MCA Doppler is particularly useful because the peak systolic velocity increases in anemia, providing an indirect but reliable indicator of the condition. This technique is essential for guiding management in cases of suspected fetal anemia, especially due to conditions like Rh isoimmunization</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 303, Williams Obstetrics 25<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 75309,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18839,
      "choices": [
        {
          "id": 75316,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Arrange for cordocentesis and consider Intra uterine transfusion if PCV &lt; 30%</span></span></span></span></p>"
        },
        {
          "id": 75317,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Give Betamethasone for fetal lung maturity and deliver. </span></span></span></span></p>"
        },
        {
          "id": 75318,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Amniocentesis for amniotic fluid spectrophotometry</span></span></span></span></p>"
        },
        {
          "id": 75319,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Repeat a PSV of the MCA after &nbsp;2 weeks</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year G3P2 presented to the Antenatal clinic at 28 weeks. Her blood group is B neg and her partners blood group is B +. Indirect Coombs test revealed high titers and an MCA revealed an increased diastolic flow &gt; 1.5 MoM with a normal peak systolic velocity. Which of the following is correct?</span></span></p>",
      "unique_key": "Q9063269",
      "question_audio": null,
      "question_video": null,
      "map_id": 18663,
      "difficulty_level": "difficult",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. D.&nbsp;</span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Repeat a PSV of the MCA after 2 weeks</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">In the scenario given, it is mentioned that the peak systolic velocity (PSV) is normal. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">The patient needs to be followed up. </span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Only when the PSV&gt; 1.5 MoM; should a cordocentesis be done</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Let us look at each option:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option A. Arrange for cordocentesis and consider intrauterine transfusion if PCV &lt; 30%:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Cordocentesis is a procedure to obtain fetal blood and assess hematocrit (PCV). Intrauterine transfusion is considered if fetal anemia is confirmed. However, this step might be premature if only the diastolic flow in the MCA is increased, and the peak systolic velocity (PSV) is normal. Cordocentesis carries risks and is typically considered when there&#39;s clear evidence of fetal anemia.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option B. Give Betamethasone for fetal lung maturity and deliver:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Administering Betamethasone and planning for delivery would be considered if there&#39;s evidence of significant fetal compromise and the pregnancy is at a stage where delivery is viable. At 28 weeks, unless there is urgent evidence of severe fetal distress, immediate delivery is not typically the first choice.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option C. Amniocentesis for amniotic fluid spectrophotometry:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Amniotic fluid spectrophotometry is used to measure bilirubin levels, which can indicate fetal hemolysis. However, with the advent of non-invasive methods like MCA Doppler, its use has decreased</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option D. Repeat a PSV of the MCA after 2 weeks (Correct Answer):&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Since the peak systolic velocity of the MCA is normal, indicating no immediate severe fetal anemia, monitoring with a repeat MCA Doppler in 2 weeks is a prudent approach. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Educational Objective:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">In cases of suspected fetal anemia due to Rh incompatibility, monitoring with repeated MCA Doppler studies is crucial, especially when initial findings are borderline or inconclusive. This approach allows for close surveillance of the fetus and helps in deciding the appropriate time for interventions like cordocentesis or intrauterine transfusion.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 303, Williams Obstetrics 25<sup>th</sup> edition</span></span></strong></p>",
      "correct_choice_id": 75319,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18840,
      "choices": [
        {
          "id": 75320,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">350 nm</span></span></span></span></p>"
        },
        {
          "id": 75321,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">400 nm</span></span></span></span></p>"
        },
        {
          "id": 75322,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">450 nm</span></span></span></span></p>"
        },
        {
          "id": 75323,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">500 nm</span></span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">On amniotic fluid spectrophotometry, optical density of bilirubin peaks at a wavelength of? </span></span></p>",
      "unique_key": "Q4169973",
      "question_audio": null,
      "question_video": null,
      "map_id": 18664,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. C. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">450 nm</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">On spectrophotometry, bilirubin levels peak at an optical density wavelength of 450 nm</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Bilirubin in amniotic fluid has a peak absorption at around 450 nm, which is in the blue region of the visible spectrum. This characteristic peak is used in spectrophotometry to assess the level of bilirubin and, by extension, the degree of fetal hemolysis.&nbsp;</span></span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Thus option A) is correct.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Educational Objective:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">In amniotic fluid spectrophotometry, bilirubin, an indicator of fetal hemolysis, peaks at an optical density of 450 nm. This knowledge is essential in assessing the severity of fetal hemolytic disease, such as in cases of Rh incompatibility, and guides subsequent management decisions.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 304, Williams Obstetrics 25<sup>th</sup> edition</span></span></strong></p>",
      "correct_choice_id": 75322,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18841,
      "choices": [
        {
          "id": 75324,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">O positive</span></span></span></span></p>"
        },
        {
          "id": 75325,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Irradiated</span></span></span></span></p>"
        },
        {
          "id": 75326,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Leukocyte poor</span></span></span></span></p>"
        },
        {
          "id": 75327,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">80% PCV</span></span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All are features of the blood transfused in intra-uterine blood transfusion except?</span></span></p>",
      "unique_key": "Q9634121",
      "question_audio": null,
      "question_video": null,
      "map_id": 18665,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. A. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">O positive</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Intra-uterine transfusion is done using: Red cells which are:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Freshly donated</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">O neg</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">CMV neg</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">80% PCV</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Irradiated </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Leukocyte poor</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Let us look at each option:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option A. O positive (Answer):&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">O positive blood is not typically used for intrauterine transfusion, especially if the fetus is Rh negative. The ideal blood type for intrauterine transfusion is O negative, RhD negative, to avoid Rh sensitization and other blood type incompatibilities.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option B. Irradiated:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Blood used in intrauterine transfusions should be irradiated. This prevents transfusion-associated graft-versus-host disease, a rare but serious complication.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option C. Leukocyte poor:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">The blood should be leukocyte poor (or leuko-reduced), meaning that white blood cells are removed. This reduces the risk of febrile non-hemolytic transfusion reactions and CMV transmission.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option D. 80% PCV:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Blood for intrauterine transfusions is often concentrated to a hematocrit (PCV, packed cell volume) of about 80% to deliver a higher amount of red blood cells in a smaller volume, which is necessary due to the limited space in the fetal circulation.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Educational Objective:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">For intrauterine blood transfusions, the ideal blood type is O negative, RhD negative, and the blood should be irradiated and leukocyte poor, with a high packed cell volume (about 80%). These specifications are critical to ensure the safety and effectiveness of the transfusion for the fetus</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 304, Williams Obstetrics 25<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 75324,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18842,
      "choices": [
        {
          "id": 75328,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Trisomy 18</span></span></span></span></p>"
        },
        {
          "id": 75329,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Turner syndrome</span></span></span></span></p>"
        },
        {
          "id": 75330,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Klinefelter syndrome</span></span></span></span></p>"
        },
        {
          "id": 75331,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Trisomy 13</span></span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most common aneuploidy causing non-immune hydrops is?</span></span></p>",
      "unique_key": "Q4516847",
      "question_audio": null,
      "question_video": null,
      "map_id": 18666,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. B. </span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Turner syndrome</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Etiology for non immune hydrops:</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"list-style-type:none\">&nbsp;</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Aneuploidy (20%) &ndash; MC: 45 XO (Turner Syndrome)</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cardiovascular (15%)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Infections (15%) &ndash;Most common &ndash; Parvovirus B19</span></strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Let us look at each option:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option A. Trisomy 18:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">It is also known as Edwards syndrome ,it is associated with a high rate of fetal anomalies and mortality. While it can cause hydrops, it is not the most common aneuploidy leading to this condition.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option B. Turner Syndrome (Correct Answer):&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Turner syndrome, characterized by a missing or structurally altered X chromosome, is the most common aneuploidy associated with non-immune hydrops fetalis. Common features include lymphatic dysplasia, which can lead to fluid accumulation and hydrops.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option C. Klinefelter Syndrome:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Klinefelter syndrome is a genetic condition affecting males, where they have an extra X chromosome (XXY). It is not typically associated with non-immune hydrops fetalis as the most common cause.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option D. Trisomy 13:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Trisomy 13, or Patau syndrome, is a severe chromosomal abnormality with multiple anomalies. Like Trisomy 18, it can be associated with hydrops, but it is not the most common cause.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Educational Objective:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Turner syndrome is the most common aneuploidy causing non-immune hydrops fetalis. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 309, Williams Obstetrics 25<sup>th</sup> edition</span></span></strong></p>",
      "correct_choice_id": 75329,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18844,
      "choices": [
        {
          "id": 75336,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">CMV</span></span></span></span></p>"
        },
        {
          "id": 75337,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Herpes</span></span></span></span></p>"
        },
        {
          "id": 75338,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Parvovirus B19</span></span></span></p>"
        },
        {
          "id": 75339,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Toxoplasma</span></span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most common infectious cause of non-immune hydrops is:</span></span></p>",
      "unique_key": "Q1973782",
      "question_audio": null,
      "question_video": null,
      "map_id": 18667,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. C. Parvovirus B19</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Etiology:</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Aneuploidy (20%) &ndash; MC: 45 XO (Turner Syndrome)</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cardiovascular (15%)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Infections (15%) &ndash;Most common &ndash; Parvovirus B19</span></strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Let us look at each option:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option&nbsp;</span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">A. CMV (Cytomegalovirus):&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">CMV is a common virus that can infect people of all ages. While it can cause congenital infections and may result in complications in pregnancy, it is not the most common infectious cause of non-immune hydrops.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option&nbsp;</span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">B. Herpes:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Herpes simplex virus can lead to severe complications in newborns if transmitted during childbirth, but it&#39;s not typically associated with non-immune hydrops fetalis as the most common cause.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option&nbsp;</span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">C. Parvovirus B19 (Correct Answer):&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Parvovirus B19, the virus responsible for causing fifth disease (erythema infectiosum), is the most common infectious cause of non-immune hydrops fetalis. It can lead to severe anemia in the fetus, which in turn can cause heart failure and hydrops.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option&nbsp;</span></span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">D. Toxoplasma:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Toxoplasmosis, caused by the parasite Toxoplasma gondii, is a concern during pregnancy as it can lead to congenital infections. However, it is not the most common infectious cause of non-immune hydrops fetalis.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Educational Objective:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Parvovirus B19 is the most common infectious cause of non-immune hydrops fetalis. </span></span></span></span></p>\r\n\r\n<p style=\"text-align:center\">&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 309, Williams Obstetrics 25<sup>th</sup> edition</span></span></strong></p>",
      "correct_choice_id": 75338,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18846,
      "choices": [
        {
          "id": 75344,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Fluid in all 3 compartments</span></span></span></span></p>"
        },
        {
          "id": 75345,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Fluid in 1 out of 3 compartments</span></span></span></span></p>"
        },
        {
          "id": 75346,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Fluid in 2 out of 3 compartments</span></span></span></span></p>"
        },
        {
          "id": 75347,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Scalp edema and placentomegaly</span></span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrops fetalis is diagnosed on ultrasound by:</span></span></p>",
      "unique_key": "Q3527018",
      "question_audio": null,
      "question_video": null,
      "map_id": 18668,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. C. Fluid in 2 out of 3 compartments</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hydrops Fetalis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Excessive accumulation of serous fluid</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">USG Diagnosis:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> 2 or more fetal effusions OR 1 effusion + anasarca</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Usually accompanied with skin edema and placentomegaly</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">USG &ndash; clinically significant edema: &gt; 5 mm</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">USG - &gt; 4 cm in 2<sup>nd</sup> trimester/&gt; 6 cm in the 3<sup>rd</sup> trimester</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">2 causes: </span></span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Immune (Rh iso-immunization) &ndash; 10%</span></span></strong></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Non &ndash; Immune &ndash; 90%</span></span></strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"margin-left:120px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Let us look at each opion :</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option A. Fluid in all 3 compartments:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">While finding fluid in all three fetal compartments (such as ascites, pleural effusion, and pericardial effusion) is highly indicative of hydrops fetalis, this level of fluid accumulation is not necessary to make the diagnosis.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option B. Fluid in 1 out of 3 compartments:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Fluid accumulation in just one fetal compartment may not be sufficient for the diagnosis of hydrops fetalis. Other causes can lead to isolated fluid accumulations, such as chylothorax or isolated ascites.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option C. Fluid in 2 out of 3 compartments (Correct Answer):&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">The diagnosis of hydrops fetalis is typically made when there is fluid accumulation in two or more different fetal compartments. This can include ascites, pleural effusion, pericardial effusion, skin edema (anasarca), or a combination of these.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option D. Scalp edema and placentomegaly:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">While scalp edema (often seen as skin thickening) and placentomegaly (enlarged placenta) are common findings in hydrops fetalis, they alone are not sufficient for diagnosis. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Educational Objective:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Hydrops fetalis is diagnosed on ultrasound when there is fluid accumulation in two or more fetal compartments. </span></span></span></span></p>\r\n\r\n<p style=\"margin-left:96px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 309, Williams Obstetrics 25<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 75346,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18847,
      "choices": [
        {
          "id": 75348,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">10%</span></span></span></span></p>"
        },
        {
          "id": 75349,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">15%</span></span></span></span></p>"
        },
        {
          "id": 75350,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">30%</span></span></span></span></p>"
        },
        {
          "id": 75351,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">40%</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Fetal hydrops develops when the hematocrit is less than:</span></span></span></p>",
      "unique_key": "Q4479961",
      "question_audio": null,
      "question_video": null,
      "map_id": 18669,
      "difficulty_level": "difficult",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. B. 15%</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Hydrops develops when the hematocrit &lt; 15%</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Intrauterine transfusion is indicated when the hematocrit &lt; 30%</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Fetal hydrops is characterized by the accumulation of fluid in fetal compartments and tissues. It&#39;s often associated with severe anemia. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Fetal hydrops is likely to develop when the fetal hematocrit falls below 15%because&nbsp; at this level, the blood&#39;s ability to carry oxygen is significantly compromised, leading to heart failure and fluid accumulation in fetal tissues and body cavities.</span></span></span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Fetal hydrops, a condition marked by widespread fluid accumulation in the fetus, commonly develops when the fetal hematocrit falls below 15%. </span></span></span></span></p>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 305, Williams Obstetrics 25<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 75349,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 18861,
      "choices": [
        {
          "id": 75404,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Corticosteroids and delivery</span></span></span></span></p>"
        },
        {
          "id": 75405,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Plan cordocentesis and intrauterine transfusion if the Hct &lt; 30%</span></span></span></span></p>"
        },
        {
          "id": 75406,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Repeat MCA Doppler after 1 week</span></span></span></span></p>"
        },
        {
          "id": 75407,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Repeat ICT after 1 week</span></span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 34-year-old G3A2 presents at 31 weeks. She is Rh negative and her ICT is 1:32. An MCA Doppler reveals a PSV less than 1.5 MoM. What will be the next step in management?</span></span></p>",
      "unique_key": "Q7530003",
      "question_audio": null,
      "question_video": null,
      "map_id": 18725,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Ans. C. Repeat MCA Doppler after 1 week</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Management of an already sensitized pregnancy (i.e., ICT positive)</span></span></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Check ICT monthly till 24 weeks and weekly thereafter till critical titers are reached</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Critical titre is &gt; 1: 16</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">Once critical titre is reached - Check Peak systolic velocity of Middle cerebral artery (PSV of MCA) </span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">If PSV of MCA &gt; 1.5 MoM &ndash; Cordocentesis and check fetal Hematocrit (Hct)</span></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">If Hct of fetal blood is &lt; 30% - Intra uterine transfusion with O negative blood is transfused</span></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\">In this patient, the PSV of the MCA is &lt; 1.5 MoM, so repeat monitoring of MCA PSV is required.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Let us look at each option :</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option A. Corticosteroids and delivery</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">: Considered when there is evidence of fetal distress or severe fetal compromise, and the fetus is at a gestational age where delivery is feasible. In this case, since the MCA Doppler is not indicative of severe fetal anemia, immediate corticosteroids and delivery may not be necessary.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option B. Plan cordocentesis and intrauterine transfusion if the Hct &lt; 30%:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Cordocentesis is a procedure to test fetal blood and is typically considered when there&#39;s evidence of fetal anemia or distress. Intrauterine transfusion would be indicated if fetal anemia is confirmed on MCA dopler. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option C. Repeat MCA Doppler after 1 week (Correct Answer):&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Given that the current MCA Doppler reading is less than 1.5 MoM, indicating no immediate severe fetal anemia, the best course is to monitor the fetal condition closely. Repeating the MCA Doppler after 1 week allows for ongoing assessment of the fetal status and timely intervention if the situation changes.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Option D. Repeat ICT after 1 week:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">While monitoring the ICT can provide information on the progression of the mother&rsquo;s antibody levels, it does not directly assess the fetal condition. </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">Educational Objective:&nbsp;</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:#374151\">In cases where an Rh-negative woman has a positive ICT but the fetal MCA Doppler PSV is less than 1.5 MoM, indicating no immediate severe fetal anemia, the best management approach is to closely monitor the fetal condition with repeated MCA Doppler assessments. This strategy allows for timely detection and intervention if fetal anemia develops.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 303, Williams Obstetrics 25<sup>th</sup> edition</span></span></strong></p>",
      "correct_choice_id": 75406,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}